WLWanlin Lei

Wanlin Lei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wanlin Lei has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Maofeng Wang

    Department of Biomedical Sciences Laboratory, Affiliated Dongyang Hospital, Wenzhou Medical University, Dongyang, Zhejiang, China

    2 shared publications
  • Chenchen Yi

    Zhejiang Provincial Key Laboratory of Medical Genetics, College of Laboratory Medicine and Life sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China

    1 shared publication
  • Jianling Qiang

    Department of Biomedical Sciences Laboratory , Affiliated Dongyang Hospital of Wenzhou Medical University , Dongyang , Zhejiang , China

    1 shared publication
  • Lili Xu

    Department of Obstetrics, Affiliated Dongyang Hospital, Wenzhou Medical University, Dongyang, Zhejiang, China

    1 shared publication
  • Xiuyan Li

    Intensive Care Unit, Affiliated Dongyang Hospital, Wenzhou Medical University, Dongyang, Zhejiang, 322100, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Global epidemiology of thyroid cancer: trends in incidence, mortality, and DALYs from 1990 to 2021

    by Wanlin Lei, Jianling Qiang, Chenchen Yi, Maofeng Wang

    Objectives: This study provides the first comprehensive assessment of the global thyroid cancer burden from 1990 to 2021, focusing on incidence, mortality, and DALYs trends across 204 countries. Methods: Using Global Burden of Disease (GBD) 2021 data, age-standardized rates (ASRs) and estimated annual percentage changes (EAPCs) were calculated. Associations with the Socio-demographic Index (SDI) were analyzed via linear regression. Results: Globally, the age-standardized incidence rate increased from 2.06 to 2.91 per 100,000 (EAPC=1.25), with women accounting for 67 % of cases. Mortality showed a modest decline (EAPC=−0.23), but DALYs remained high (14.57 million in 2021). High-SDI regions, such as North America, accounted for 72 % of cases, reflecting intensive screening, whereas low-SDI regions, particularly Sub-Saharan Africa, contributed 68 % of deaths due to delayed diagnosis. High BMI contributed 1.68 % of DALYs, peaking at 4.26 % in Andean Latin America. Incidence varied significantly across countries, from 7.13 per 100,000 in Saudi Arabia (linked to iodine excess) to 0.014 per 100,000 in Tajikistan (iodine deficiency). Mortality was highest among elderly males, reaching 12.57 per 100,000 in those aged ≥90 years. Conclusions: The rising global burden of thyroid cancer highlights pronounced gender and regional disparities. High-SDI regions should prioritize risk-stratified strategies to reduce overdiagnosis, while low-SDI regions require improved access to healthcare. Targeted efforts in early detection and metabolic risk reduction are critical to mitigate disease burden.


  • Open Access

    Risk Stratification for Cephalosporin-Induced Thrombocytopenia: Development and Validation of a Multidimensional Predictive Model in Older Adults

    by Xiuyan Li, Wanlin Lei, Maofeng Wang, Lili Xu

    Objective: Third-generation cephalosporins, while widely prescribed, carry underquantified thrombocytopenia risks in older adults. This study aimed to develop and validate a clinical prediction model for cephalosporin-associated thrombocytopenia in hospitalized patients aged over 65 years. Methods: A retrospective cohort (2019~2023) initially included 45,779 cephalosporin treated patients. After applying exclusion criteria, 12,917 patients were analyzed. Predictors were selected via LASSO regression, with backward elimination multivariate logistic regression constructing a nomogram. Model performance was assessed using AUC, calibration curves, and decision curve analysis (DCA) in training and testing sets. Results: The final model identified eight predictors: baseline platelet count (PLT), red blood cell count (RBC), presence of tumor, renal insufficiency (RI), liver cirrhosis (LC), meropenem use, use of antifungal drugs (AD), and daily usage frequency (DUF). It demonstrated strong discrimination (training AUC 0.82 [95% CI 0.79– 0.85]; testing AUC 0.80 [0.76– 0.84]) and calibration (Brier score 0.057). DCA confirmed clinical utility across wide risk thresholds. Conclusion: This nomogram tool enables rapid thrombocytopenia risk assessment in elderly patients receiving cephalosporins. Clinically, it guides antibiotic selection by quantifying comorbidity-drug interactions, and improves toxicity monitoring accuracy in complex geriatric cases with polypharmacy.